HLS Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Craig Millian

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage26.92%
CEO tenure2yrs
CEO ownership0.04%
Management average tenure4.5yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Craig Millian's remuneration changed compared to HLS Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$18m

Dec 31 2024n/an/a

-US$20m

Sep 30 2024n/an/a

-US$22m

Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$1mUS$381k

-US$28m

Compensation vs Market: Craig's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD499.93K).

Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.


CEO

Craig Millian (56 yo)

2yrs
Tenure
US$1,414,327
Compensation

Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...


Leadership Team

NamePositionTenureCompensationOwnership
Craig Millian
CEO & Director2yrsUS$1.41m0.040%
€ 39.9k
John Hanna
CFO & Non-Independent Director1.3yrsUS$110.39k0.025%
€ 25.5k
Jason Gross
Vice President of Scientific Affairs10.9yrsUS$313.47k0.16%
€ 158.6k
Ryan Lennox
Senior VP of Legal7yrsUS$418.09k0.0016%
€ 1.6k
Brian Walsh
Chief Commercial Officer1.9yrsUS$437.71k0.0038%
€ 3.8k
Dave Mason
Investor Relations Officerno datano datano data
David Spence
VP & Corporate Controller7.3yrsno datano data
4.5yrs
Average Tenure
56yo
Average Age

Experienced Management: 74D's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Craig Millian
CEO & Director2yrsUS$1.41m0.040%
€ 39.9k
John Hanna
CFO & Non-Independent Director1.9yrsUS$110.39k0.025%
€ 25.5k
John Welborn
Independent Chairman of the Board3.9yrsUS$248.89k0.45%
€ 450.9k
Christine Elliott
Independent Directorless than a yearno datano data
Rodney Hill
Independent Director7.2yrsUS$220.00kno data
Norma Beauchamp
Independent Director3.9yrsUS$207.50k0.0016%
€ 1.6k
Kyle Dempsey
Independent Director2.5yrsUS$209.50k0.0056%
€ 5.6k
Christian Roy
Independent Director1.9yrsUS$112.49kno data
2.3yrs
Average Tenure
57.5yo
Average Age

Experienced Board: 74D's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 00:16
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
George UlybyshevClarus Securities Inc.